Related Experiment Video
Updated: Jun 16, 2026
10:47
Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
Published on: February 3, 2015
OXavidin for tissue targeting biotinylated therapeutics.
Rita De Santis1, Claudio Albertoni, Antonio Rosi
1Immunology Department, Sigma-Tau SpA R&D, Pomezia, 00040 Rome, Italy. rita.desantis@sigma-tau.it
Journal of Biomedicine & Biotechnology
|February 5, 2010
Summary
Researchers developed OXavidin, a modified avidin that binds to tissues for weeks. This artificial receptor enables targeted delivery of biotinylated therapies to tumors and cells, showing great therapeutic potential.
Area of Science:
- Biochemistry
- Biotechnology
- Medical Imaging and Diagnostics
Background:
- Avidin, a glycoprotein from hen egg white, exhibits high-affinity biotin binding.
- Current limitations in targeted drug delivery necessitate novel biomaterials for enhanced therapeutic efficacy.
Purpose of the Study:
- To develop OXavidin, a modified avidin with aldehyde groups for improved tissue retention and biotin-binding capacity.
- To evaluate OXavidin's potential as an "artificial receptor" for targeted delivery of biotinylated therapeutics and cells.
Main Methods:
- Ligand-assisted sugar oxidation of avidin using sodium periodate to create OXavidin.
- Chemical reaction of OXavidin with cellular and tissue proteins via Schiff's base formation.
- Immunohistochemistry to assess OXavidin's tissue localization and residence time.
Main Results:
- OXavidin demonstrated long-term residence in both normal and neoplastic tissues (weeks) via Schiff's base formation.
- Immunohistochemistry revealed strong and homogeneous stromal localization of OXavidin and its complexes.
- OXavidin successfully functioned as an artificial receptor for targeted delivery of biotinylated agents.
Conclusions:
- OXavidin offers prolonged tissue localization and retains biotin-binding capacity, making it a promising platform for targeted therapies.
- The "artificial receptor" capability of OXavidin facilitates tumor targeting with biotinylated therapeutics (radioisotopes, toxins) and cell homing.
- OXavidin presents significant potential for diverse therapeutic applications, including cancer treatment and cell-based therapies.
Related Concept Videos
03:31Labeling DNA Probes
DNA probes are fragments of DNA labeled with a reporter tag to enable their detection or purification. The resulting labeled DNA probes can then hybridize to target nucleic acid sequences through complementary base-pairing, and may be used to recover or identify these regions.
Radioisotopes, fluorophores, or small molecule binding partners like biotin or digoxigenin, are the most widely used reporter tags for labeling DNA probes. These labels can be attached to the probe DNA molecule via...
Radioisotopes, fluorophores, or small molecule binding partners like biotin or digoxigenin, are the most widely used reporter tags for labeling DNA probes. These labels can be attached to the probe DNA molecule via...
01:21Drug Distribution: Tissue Binding
Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
For...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.